Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference

    Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference

Presentation Scheduled for Monday, March 18th at 10:00 AM PT

PR Newswire

NEW YORK, March 14, 2013

NEW YORK, March 14, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the upcoming 25th Annual ROTH Conference, to be
held March 17^th -20^th in Dana Point, California. Mr. Bentsur's presentation
is scheduled to take place on Monday, March 18^th, at 10:00 AM PT (1:00 PM
ET).

A live audio webcast of Mr. Bentsur's presentation will be accessible from the
Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of the webcast will be
available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3
clinical program for Zerenex for the treatment of hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease, conducted pursuant
to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx
expects to submit a New Drug Application with the FDA in the second quarter of
2013 and a Marketing Authorization Application with the EMA in mid-2013.
Zerenex is also in Phase 2 development in the U.S. for the management of
phosphorus and iron deficiency in anemic patients with Stages 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its
New Drug Application for marketing approval of ferric citrate in Japan for the
treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx
is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://investors.keryx.com
 
Press spacebar to pause and continue. Press esc to stop.